PELOBiotech offers monoclonal antibodies such as R-17F, A1, and mAb-A4, specifically targeting glycan epitopes on undifferentiated iPSCs. These functional antibodies are ideal for selectively eliminating residual pluripotent cells, enhancing the safety of stem cell-based research and applications.